Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
Nicolas Gendron, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and Nûn Kalim Bentounes co-authored, published in Journal of Thrombosis and Haemostasis, adding:
“Very happy to have been invited to write this comment with Nûn Bentounes for Journal of Thrombosis and Haemostasis (JTH), following the very nice study by Mohamed Ghalloussi, Georges Jourdi and Demagny Julien, showing the possibility of using pre-loaded activated carbon tubes (DOAC-Stop) published in the same journal.
The DOAC become undetectable in more than 96% of cases. Routine and specialized hemostasis tests (AT, PC, PS, lupus anticoagulant, etc.) find reliable and interpretable values. A simple, elegant and upstream solution
DOAC interference and resulting diagnostic errors result in uninterpretable results, repeated examinations, wasted resources, and unnecessary patient travel, all of which are incompatible with the emerging concept of sustainable anticoagulation and its true environmental cost.
Beyond innovation, this editorial gives us the opportunity to ask a more fundamental question:
Do we really need all these hemostasis tests in patients on DOACs?
The answer: often, no. In particular for thrombophilia check-ups, which are still too often prescribed and do not comply with the recommendations.
Our message: to combine this innovation with computerized prescribing systems, which guide clinicians to the right examination, for the right patient, at the right time with the right tube, and a robust antithrombotic stewardship program.”
Title: Charcoal for direct oral anticoagulant removal: toward appropriate prescribing and sustainable anticoagulation?
Authors: Nûn Kalim Bentounes, Nicolas Gendron
Other posts featuring Nicolas Gendron on Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies